Research progress of tumor-associated macrophages in glioblastoma
Objective To summarize the latest research progress of tumor-associated macrophages(TAMs)in glioblastoma(GBM).Methods Using"glioblastoma,tumor-associated macrophages,metabolize,radiochemotherapy,targeted thera-py"as English and Chinese keywords,relevant literature was searched in the PubMed and CNKI databases from January 1,2005,to December 31,2023.Inclusion criteria:(1)Source of tumor-associated macrophages in GBM and polarization;(2)The influence of tumor-associated macrophages on GBM cells;(3)The influence of GBM microenvironment metabo-lism on tumor-associated macrophages;(4)TAMs as the target of GBM therapy and their effects on radiotherapy,chemo-therapy and targeted therapy.Exclusion criteria:(1)Literature with duplicate contents;(2)Literature with imperfect research data;(3)Literature with less correlation with this study.According to the inclusion criteria and exclusion crite-ria,58 articles met the analysis.Results TAMs are divided into two different polarized phenotypes,the M1 phenotype that inhibits tumor growth and the M2 phenotype that promotes tumor growth.M1/M2 polarization is a dynamic and re-versible process.TAMs are abundant in glioblastoma tissues,among which M2 type TAMs account for a high propor-tion.TAMs and GBM cells interact and influence each other.TAMs can promote tumor cell proliferation and invasion,maintain an immunosuppressive tumor microenvironment(TME),and lead to treatment resistance,which is related to the poor prognosis of GBM;abnormal metabolism of tumor cells can also change the microenvironment and affect the phe-notypic polarization of TAMs.TAMs are a potential therapeutic target for GBM.Conclusions In GBM,tumor-associat-ed macrophages can promote the proliferation,invasion,blood vessel formation,and the formation of an immunosuppres-sive microenvironment.Combining radiation or chemoradiation with targeted TAMs will enable better GBM therapy,and therapeutic strategies targeting TAMs will benefit more GBM patients in the future.